Sanochemia Pharmazeutika AG announces grant of patent for Vidon® Photodynamic Therapy of Bladder Cancer in the USA

Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307 ISIN DE000A1G7JQ9), announces that the United States Patent and Trademark Office has issued “Notice of Allowance“ for Vidon® in Photodynamic Therapy (PDT) of bladder cancer.

Vidon® (PVP-Hypericin) is one of Sanochemia`s promising pipeline products and is being developed as a game changing technology in the management of bladder cancer. The patent covers the method for therapy of bladder cancer with Sanochemia’s developed PVP-Hypericin formulation. The U.S. patent will protect Vidon® until 2035.

 “The Notice of Allowance for the US application of Vidon® for PDT is an important milestone to secure the long-term value of Vidon® for Sanochemia”, said Dr. Christina Abrahamsberg, CSO of Sanochemia Pharmazeutika AG.

Bladder cancer is the most common malignancy of the urinary tract. Approximately 75% of initially diagnosed bladder cancers are non-muscle invasive tumors, which means that the tumor is restricted to the mucosa. In 30-80% of the patients, recurrences occur, requiring repeated surgeries. About 45% of bladder cancers will progresses to a muscle-invasive bladder carcinoma.

Early detection, timely and appropriate treatment are therefore essential factors for improving the prognosis of urinary bladder carcinoma patients.  

Photodynamic therapy (PDT) is a method of treating bladder tumors with a photosensitizer and light. The method is based on the selective accumulation of the photosensitizer in malignant cells and the irradiation of the tumor tissue with light of a specific wavelength. Subsequently, photochemical processes generate toxic substances that specifically damage the tumor.

Vidon® is developed by Sanochemia Pharmazeutika AG as a diagnostic and therapeutic option for patients with non-muscle invasive bladder cancer.